Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center, Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  osteosarcoma, Ewing sarcoma
Results 1-25 of 446 for your search:
Start Over
Cabozantinib-s-malate in Treating Patients with Relapsed Osteosarcoma or Ewing Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 9620, NCI-2014-01927, CABONE, NCT02243605
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Proton Beam Radiation Therapy in Treating Younger Patients with Bone or Non-rhabdomyosarcoma Soft Tissue Sarcomas
Status: Active
Phase: No phase specified
Type: Treatment
Age: 30 and under
Trial IDs: 05-326, NCI-2012-00673, NCT00592293
MRI in Measuring Biomarkers of Early Treatment Response in Patients With Osteosarcoma or Ewing Sarcoma
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 13 and over
Trial IDs: VICC SAR 1275, NCI-2013-01359, NCT01882231
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 20 years
Trial IDs: SPOC-2012-001, NCI-2014-02681, NCT02013336
Effect of Radiation on Bone in Patients with Cancer of the Sacrum
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 14-208, NCI-2015-00893, NCT02323295
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Status: Active
Phase: No phase specified
Type: Tissue collection/Repository
Age: 21 and under
Trial IDs: AEWS07B1, NCI-2009-00370, CDR0000544202, COG-AEWS07B1, NCT00899990
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
Randomized Phase IIb Trial of Vigil™ Versus Gemcitabine + Docetaxel for Ewing's Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 and over
Trial IDs: CL-PTL-121, NCI-2016-00417, NCT02511132
T Cell Receptor Gene Therapy in Treating Younger Patients with Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 35 and under
Trial IDs: 14-C-0059, NCI-2014-02506, P131369, NCT02107963
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 12 and over
Trial IDs: TK216-01, NCI-2016-00918, NCT02657005
Combination Chemotherapy with or without Ganitumab in Treating Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1221, NCI-2014-02380, NCT02306161
Irinotecan Hydrochloride, Temozolomide, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Ewing Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 1 to 40
Trial IDs: 13-068, NCI-2013-01094, NCT01864109
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
Stereotactic Body Radiotherapy in Treating Lung Metastases in Patients with Ewing Sarcoma, Rhabdomyosarcoma, or Wilms Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 20 and under
Trial IDs: 15-278, NCI-2016-00890, NCT02581384
Iodine I 124 Monoclonal Antibody 3F8 PET/CT in Imaging Patients with Solid Tumor
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 3 to 90
Trial IDs: 13-147, NCI-2016-00939, NCT02307630
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Olaparib and Temozolomide with or without Irinotecan in Treating Patients with Recurrent or Metastatic Ewing Sarcoma Previously Treated with Chemotherapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-115, NCI-2013-01821, NCT01858168
Denosumab in Treating Patients with Recurrent or Refractory Osteosarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 11 to 49
Trial IDs: AOST1321, NCI-2015-00543, NCT02470091
Start Over